On WHO’s essential medicines process and transparencyBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5637 (Published 17 September 2014) Cite this as: BMJ 2014;349:g5637
- Nicola Magrini, scientist1,
- Jane Robertson, technical officer1,
- Kees de Joncheere, director1,
- Lisa Bero, professor and chair of WHO expert committees on the selection and use of essential medicines in 2011 and 20132
- 1Essential Medicines List Secretariat, Essential Medicines and Health Products Department, World Health Organization, 1211 Geneva 27, Switzerland
- 2Medicines Use and Health Outcomes, Faculty of Pharmacy and Charles Perkins Centre, University of Sydney, Sydney, Australia
Barbui and Purgato have critiqued the processes used to select WHO’s list of essential medicines and provided suggestions on how it could be improved.1
As mentioned, reforms in 2001 substantially changed the way that the expert committee reviews submissions, introducing systematic evidence synthesis and appraisal as a requirement, along with an assessment of comparative cost and cost effectiveness. In addition, WHO made the processes transparent, with all submitted data and reviews publicly available, and introduced opportunities for public comment.
The authors raise three major issues regarding …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial